19.11.20 @ 03:11 < Back

Out HIT Program portfolio is growing

We welcome GlaucoT to our HİT Portfolio! GlaucoT has claimed its place in our portfolio with their product which was developed to treat glaucoma disease, one of the leading factors that causes blindness around the world. Together with our HIT Program team, GlaucoT will carry out the market penetration and business development processes for the internationally patented, noninvasive, neuroprotective, traceable personal therapy device.